JG
KERX

Jefferies Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Jefferies Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-74,000
Closed -$344K – 2967
2017
Q4 		$344K Buy
+74,000
New +$408K ﹤0.01% 1942
2015
Q3 		– Sell
-10,900
Closed -$73K – 3448
2015
Q2 		$109K Buy
+10,900
New +$117K ﹤0.01% 2184
2014
Q1 		– Sell
-7,290
Closed -$94K – 2524
2013
Q4 		$94K Buy
+7,290
New +$87.1K ﹤0.01% 1707
2013
Q3 		– Sell
-120
Closed -$1K – 2317
2013
Q2 		$1K Buy
+120
New +$938 ﹤0.01% 1823

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jefferies Group's KERX Position: Q1 2018 in Review

Jefferies Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 74,000 shares — an estimated $344K sold.

Jefferies Group first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $344K in Q4 2017. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Jefferies Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Jefferies Group sold 74,000 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $344K.
  • Jefferies Group first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Jefferies Group's Keryx Biopharmaceuticals Inc position peaked at $344K in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Jefferies Group's 13F filing for Q1 2018, filed 15 May 2018.